53971-22-5

Usage

Uses

Used in Pharmaceutical Industry:
2H-1,2,4-Benzothiadiazine-3-acetic acid ethyl ester 1,1-dioxide is used as a precursor in the synthesis of various drugs for its potential antihypertensive and diuretic properties. It is valued for its ability to contribute to the development of medications that can help regulate blood pressure and promote the removal of excess fluid from the body.
Used as a Vasodilator:
In the medical field, 2H-1,2,4-Benzothiadiazine-3-acetic acid ethyl ester 1,1-dioxide is used as a vasodilator to help widen blood vessels, thereby improving blood flow and reducing the workload on the heart. This application is particularly beneficial for individuals suffering from cardiovascular conditions.
Used as an Anti-Inflammatory Agent:
2H-1,2,4-Benzothiadiazine-3-acetic acid ethyl ester 1,1-dioxide is also utilized as an anti-inflammatory agent, which can help reduce inflammation and associated pain in various parts of the body. This makes it a potential candidate for the treatment of conditions characterized by inflammation.
Used in Treatment of Retinal Degenerative Diseases:
2H-1,2,4-Benzothiadiazine-3-acetic acid ethyl ester 1,1-dioxide is studied for its potential applications in treating retinal degenerative diseases. Its use in this context is based on the compound's ability to target specific pathways involved in the progression of such diseases, offering a potential therapeutic approach to slow down or halt vision loss.
Used in Cardiovascular Condition Treatment:
2H-1,2,4-Benzothiadiazine-3-acetic acid ethyl ester 1,1-dioxide is being explored for its use in treating cardiovascular conditions due to its vasodilatory and anti-inflammatory properties, which can help manage symptoms and potentially improve patient outcomes in cardiovascular health.

InChI:InChI=1/C11H12N2O4S/c1-2-17-11(14)7-10-12-8-5-3-4-6-9(8)18(15,16)13-10/h3-6H,2,7H2,1H3,(H,12,13)

Upstream product

• 222420-33-9 ethyl ester 2-aminosulfonylanilide of 2-sulfonylmalonic acid 
• 62-53-3 aniline 
• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 50881-48-6 N-chlorosulfonyl-N'-phenyl-urea 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 

Relevant academic research and scientific papers

Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b.

3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase

Recently, we disclosed a new class of HCV polymerase inhibitors discovered through high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection. This interesting class of 3-(1,1-dioxo-2H-1,2,4- benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones potently inhibits HCV polymerase enzymatic activity and inhibits the ability of the subgenomic HCV replicon to replicate in Huh-7 cells. This report will focus on the structure-activity relationships (SAR) of substituents on the quinolinone ring, culminating in the discovery of 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4- benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone (130), an inhibitor with excellent potency in biochemical and cellular assays possessing attractive molecular properties for advancement as a clinical candidate. The potential for development and safety assessment profile of compound 130 will also be discussed.

PYRIDAZINONE COMPOUNDS

The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Anti-infective agents

Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Recyclization of 2-imino-2H-1-benzopyrans under the influence of nucleophilic reagents. 2. Reaction of 2-iminocoumarin-3-carboxamides with o-aminobenzenesulfonamide

2-Iminocoumarin-3-carboxamides recyclized into 3-(1,1-dioxo-2H-benzo-1,2,4-thiadiazinyl-3)coumarins under the influence of o-aminobenzenesulfonamide. An alternative method of synthesis is discussed. Proposed mechanisms for the recyclization are discussed.